Mistra Pharma

Leading organisations:
Foundation for Strategic Environmental Research (Sweden), KTH Royal Institute of Technology (Sweden), Umeå University (Sweden), University of Gothenburg (Sweden), Uppsala University (Sweden), and Brunel University West London (United Kingdom)

Timeframe:
2008-2015

Geographic Area:
British Isles Scandinavia

Objectives:

To identify and reduce environmental risks caused by the use of human pharmaceuticals.


Target audience:
National/Local decision and policy makers, Pharmaceutical manufacturers, Scientists, and Waste/water treatment providers

Area of interest:
Emergence of anti-microbial resistance (AMR), Occurrence of pharmaceuticals in the environment, Pharmaceutical consumption by humans, Risks to ecosystems, Risks to human health, Wastewater, and Water treatment technologies

Activities:

1) To identify human pharmaceuticals that are likely to be of concern to aquatic ecosystems, 2) To address the risk for antibiotic resistance promotion in the environment, 3) To propose risk management strategies, in particular, improved regulatory test requirements and wastewater treatment technologies.


Communication material:

Return to search form.

HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE+ programme, the Federal Ministry for the Environment, Nature Conservation, and Nuclear Safety (BMU) Germany, and the German Environment Agency (UBA). HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC, BMU, or UBA.